XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Process Analytical Technology has been an FDA regulatory priority since 2004. The PAT guidance was published two decades ago. ICH Q8, Q10, and Q13 all reference PAT as a cornerstone of the modern quality
View details →
ICH Q8(R2) was finalized in 2009. ICH Q11 was published in 2012. Fifteen-plus years of regulatory infrastructure for Quality by Design, and the biologics BLA failure mode for QbD submissions has not changed: the
View details →
The compendial sterility test carries well-documented sensitivity limitations: with the standard sample size drawn from a batch, a lot with a very low contamination rate has only a small probability of actually triggering a
View details →
Every pharmaceutical quality director knows that Stage 3 Continued Process Verification requires ongoing process monitoring using statistical methods — FDA's 2011 Process Validation Guidance says this explicitly. And every pharmaceutical manufacturing site has implemented
View details →
Mechanistic and hybrid process models are now routine in pharmaceutical process development — population balance models for granulation and crystallization, computational fluid dynamics for mixing scale-up, first-principles droplet evaporation models for spray drying. FDA
View details →
The pharmaceutical industry has been implementing electronic batch records for more than two decades. 21 CFR Part 11 was issued in 1997. FDA's predicate rule for batch records — 21 CFR 211.188 — has
View details → Dissolution testing is the most frequently performed analytical test in pharmaceutical quality control. Every oral drug product has a dissolution specification. But for modified-release oral drug products — extended release, delayed release, gastro-retentive —
View details → Pharmaceutical manufacturing has invested heavily in Pharma 4.0: process historians capturing millions of data points per batch, manufacturing execution systems tracking every material movement and operator action, LIMS integrating in-process and release testing data
View details → The original ICH Q9(R1) guideline for quality risk management was issued in 2005. The pharmaceutical industry adopted FMEA as the standard QRM tool, built risk assessments into CMC process characterization, design space definition, and
View details → Design of Experiments is the foundation of modern pharmaceutical process characterization, and every CMC team running DOE studies for a design space submission believes their methodology is sound. The deficiency letters tell a different
View details →
Every gene therapy program reaches a scale-up decision point where the research process — T-flask, serum-containing media, research-grade reagents, milligram-scale purification — must become a GMP manufacturing process capable of producing clinical and commercial
View details → Single-use bioreactors, single-use mixing bags, and single-use filling systems have become the infrastructure standard for biopharmaceutical manufacturing. The adoption rate is high and the operational advantages are well-documented. What is less well-documented is the
View details → Long-acting PLGA microsphere formulations are commercially validated — FDA-approved PLGA microsphere LAI products have been on the market since the late 1980s. The polymer degradation mechanism, the emulsion solvent evaporation manufacturing process, and the
View details → Doxil was approved in 1995. Onpattro was approved in 2018. Between them, they bracket over two decades of liposome and lipid nanoparticle regulatory evolution — from the first PEGylated liposomal drug product through the
View details → Abraxane was approved in 2005. The nab-technology platform — albumin-bound nanoparticles manufactured by high-pressure homogenization — is one of the most commercially validated nanomedicine platforms in oncology. The mechanism is understood: albumin's interaction with
View details → Cyclodextrin complexation is one of the oldest and most commercially validated solubilization technologies in pharmaceutical formulation. HP-β-CD was approved as a parenteral excipient in the early 1990s, and SBE-β-CD is now in numerous FDA-approved
View details → Every ADC CMC team knows that drug-to-antibody ratio is the critical quality attribute that defines ADC potency and PK behavior. The HIC-HPLC method for DAR determination is well-established. The drug load species are characterized
View details → Radiopharmaceutical CMC shares almost nothing with standard pharmaceutical CMC except the regulatory framework it sits within. The drug substance is a radioisotope — its "purity" is measured in becquerels and percentages of radioactive decay
View details →